Tirzepatide

Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It received FDA approval as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023.Reported areas of research interest:Up to 22.5% body-weight reduction at the 15 mg dose (SURMOUNT-1 trial)Superior HbA1c reductions vs. semaglutide in head-to-head trialsDual-receptor activation producing complementary metabolic effectsOnce-weekly subcutaneous dosingPreferential reduction of visceral adipose tissueSpecification: 10 mg per vial · 99%+ purity · lyophilized powder · for laboratory and research use only. Not for human or veterinary use.

• Supplied as a lyophilized powder for laboratory reconstitution.
• HPLC purity and mass-spec identity verified on every lot.
• Backed by a lot-specific Certificate of Analysis.
• Strictly for in-vitro research use only.

Reconstitute with bacteriostatic or sterile water as appropriate for your protocol. Store reconstituted material refrigerated and use within the timeframe indicated by your research procedures.